Ilaria Del Giudice | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial	THE LANCET. HAEMATOLOGY	2024
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	HAEMATOLOGICA	2024
A case of posterior reversible encephalopathy syndrome (PRES) in an elderly patient with advanced classical Hodgkin Lymphoma during frontline treatment with brentuximab vedotin plus AVD	LEUKEMIA & LYMPHOMA	2024
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience	HEMASPHERE	2024
Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia	CANCERS	2024
Sialylation regulates migration in chronic lymphocytic leukemia	HAEMATOLOGICA	2023
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.	BRITISH JOURNAL OF HAEMATOLOGY	2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi	HEMASPHERE	2023
Achieving the Cure of Follicular Lymphoma: is it Time to Finalize Treatment Strategies to Reach This Goal in a Subset of Patients?	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients	BRITISH JOURNAL OF HAEMATOLOGY	2023
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet {PCR} improve measurable residual disease monitoring in chronic lymphoid malignancies?	FRONTIERS IN ONCOLOGY	2023
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Early clearance of hairy cell leukaemia in the bone marrow after first‐line treatment with cladribine predicts a favourable outcome	BRITISH JOURNAL OF HAEMATOLOGY	2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling	BRITISH JOURNAL OF HAEMATOLOGY	2023
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	HEMATOLOGICAL ONCOLOGY	2023
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	LEUKEMIA	2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia	HAEMATOLOGICA	2022
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia	LEUKEMIA & LYMPHOMA	2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study	CANCERS	2022
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases	HEMATOLOGICAL ONCOLOGY	2022

Progetti di Ricerca

Multicentric retrospective-prospective observational study on the clinical application of the molecular profile (somatic mutations of IGHV and TP53 genes) to guide the therapeutic choices in the real-life for patients affected by chronic lymphocytic...
Monitoraggio non invasivo della leucemia linfatica cronica trattata con approcci 'chemo-free' mediante next-generation sequencing/droplet digital PCR sul DNA tumorale plasmatico circolante (ctDNA).
MUTAZIONI CLONALI E SUBCLONALI DEI GENI TP53, BTK e PLCg2 NELLA LEUCEMIA LINFATICA CRONICA PRE- E POST-TERAPIA. USO DELLE TECNICHE DI NEXT-GENERATION SEQUENCING PER LO STUDIO DELL'EVOLUZIONE CLONALE DELLA MALATTIA E DEI MARCATORI ASSOCIATI ALLA REFR...